SCHEMBL10043875

SCHEMBL10043875

Cc1cc2c(cn1)cc(-c1cc(NC(=O)NC(=O)c3ccc(Cl)nc3)ccc1C)c(=O)n2C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
TDP1 Q9NUW8 1/20 0.42
KCNQ3 O43525 2/20 0.41
KCNQ2 O43526 2/20 0.41
SYK P43405 1/20 0.41
NPC1 O15118 2/20 0.40
KCNE1 P15382 1/20 0.39
KCNQ1 P51787 1/20 0.39
FGFR1 P11362 2/20 0.39
SRC P12931 2/20 0.39
KMT2A Q03164 4/20 0.38
MAPT P10636 3/20 0.37
MEN1 O00255 3/20 0.37
POLB P06746 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
MAPK14 Q16539 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10043851 0.91 PCTP (0.44) RAB9ASMN1; SMN2SYKNPC1FGFR1
SCHEMBL10043857 0.90 POLB (0.45) RAB9ASMN1; SMN2SYKNPC1FGFR1
SCHEMBL10043942 0.88 PCTP (0.44) RAB9ASYKNPC1FGFR1SRC
SCHEMBL10043869 0.88 GAA (0.45) RAB9ASYKNPC1MAPTPOLB
SCHEMBL13462639 0.88 SYK (0.42) RAB9ASYKNPC1FGFR1SRC
SCHEMBL10043859 0.88 SYK (0.42) RAB9ASYKNPC1FGFR1SRC
SCHEMBL10043850 0.88 SYK (0.50) RAB9ASMN1; SMN2SYKNPC1FGFR1
SCHEMBL10043948 0.87 MAPK14 (0.42) RAB9ASYKNPC1FGFR1SRC
SCHEMBL10043873 0.86 SYK (0.44) RAB9AKCNQ3KCNQ2SYKNPC1
SCHEMBL10043860 0.86 SYK (0.51) RAB9ASYKNPC1MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC RAB9A 1818/4885SMN1; SMN2 2302/4885TDP1 2356/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC RAB9A 1818/4885SMN1; SMN2 2302/4885TDP1 2356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.